atamparib   Click here for help

GtoPdb Ligand ID: 13118

Synonyms: RBN-2397 | RBN2397
PDB Ligand
Compound class: Synthetic organic
Comment: Atamparib (RBN-2397) is an orally bioavailable small molecule inhibitor of TCDD inducible poly(ADP-ribose) polymerase (TIPARP/PARP7) [1]. It was developed for potential antineoplastic and immunomodulatory actions.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 110.99
Molecular weight 523.43
XLogP 1.27
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H](COCCC(=O)N1CCN(CC1)C2=NC=C(C=N2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F
Isomeric SMILES C[C@@H](COCCC(=O)N1CCN(CC1)C2=NC=C(C=N2)C(F)(F)F)NC3=C(C(=O)NN=C3)C(F)(F)F
InChI InChI=1S/C20H23F6N7O3/c1-12(30-14-10-29-31-17(35)16(14)20(24,25)26)11-36-7-2-15(34)32-3-5-33(6-4-32)18-27-8-13(9-28-18)19(21,22)23/h8-10,12H,2-7,11H2,1H3,(H2,30,31,35)/t12-/m0/s1
InChI Key UQZCQKXJAXKZQH-LBPRGKRZSA-N
No information available.
Summary of Clinical Use Click here for help
Atamparib (RBN-2397) is a clinical candidate for cancer indications.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04053673 Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors Phase 1 Interventional Ribon Therapeutics, Inc.
NCT05127590 RBN-2397 in Combination With Pembrolizumab in Patients With SCCL Phase 1/Phase 2 Interventional Ribon Therapeutics, Inc.